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Pleasurable sexual activity is an essential component of many human relationships, providing a sense of physical, psychological,
and social well-being. Epidemiological and clinical studies show that depressive symptoms and depressive illness are associated
with impairments in sexual function and satisfaction, both in untreated and treated patients. The findings of randomized placebo-
controlled trials demonstrate that most of the currently available antidepressant drugs are associated with the development or
worsening of sexual dysfunction, in a substantial proportion of patients. Sexual difficulties during antidepressant treatment often
resolve as depression lifts but can endure over long periods andmay reduce self-esteem and affectmood and relationships adversely.
Sexual dysfunction during antidepressant treatment is typically associated with many possible causes, but the risk and type of
dysfunction vary with differing compounds and should be considered when making decisions about the relative merits and
drawbacks of differing antidepressants. A range of interventions can be consideredwhenmanaging patients with sexual dysfunction
associated with antidepressants, including the prescription of phosphodiesterase-5 inhibitors, but none of these approaches can be
considered “ideal.” As treatment-emergent sexual dysfunction is less frequent with certain drugs, presumably related to differences
in their pharmacological properties, and because current management approaches are less than ideal, a reduced burden of
treatment-emergent sexual dysfunction represents a tolerability target in the development of novel antidepressants.
1. Introduction
Systematic reviews of the epidemiology of sexual difficulties,
dysfunction, and dissatisfaction indicate that sexual problems
are common in men and women in all societies and more
frequent in older individuals and among those with chronic
medical conditions, including depression [1, 2]. For example,
the Global Survey of Sexual Attitudes and Behavior, of over
27,000 men and women aged 40–80 years, found “early
ejaculation” (i.e., rapid or premature ejaculation) to be the
most common sexual dysfunction, affecting 14% of men,
with “erectile difficulties” having a prevalence of 10% all
sexual dysfunctions in men being more prevalent in older
groups [3]. The Men’s Attitudes to Life Events and Sexuality
Study, of similar size but among men aged 20–75 years,
found the prevalence of “erectile dysfunction” to be 16%, the
proportion being higher in older men and individuals with
cardiovascular disease, hypertension, or depression [4]. The
Women’s International Study of Health and Sexuality, in over
4,500 women aged 20–70 years, found “hypoactive sexual
desire disorder” to have a prevalence range of 16–46%, in pre-
menopausal to surgically postmenopausal women [5].
There is a close and two-way relationship between the
presence of depressive symptoms and reports of sexual
difficulties and dissatisfaction. Recognizing the nature and
strength of this association, a recent international con-
sensus statement on sexual dysfunction in patients with
chronic illness recommends screening for depression [6].
The longitudinal epidemiological Zurich Study found the
prevalence of sexual problems in depressed individuals
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(including those with major depression, dysthymia, and
recurrent brief depression) to be approximately twice that in
controls (50% versus 24%) [7]. Sexual problems may be more
frequent in those with recurrent depression, as the United
States Study ofWomen’s Health Across the Nation found that
only those with recurrent episodes were significantly more
likely to report problems in sexual arousal, physical pleasure,
and emotional satisfaction, when compared to controls [8].
Given its effects on mood, energy, capacity for pleasure,
self-confidence, and self-esteem, it should be anticipated that
depression would lower sexual interest and satisfaction; and
this is the case, more markedly so in younger patients [9].
Depressive symptoms commonly coexist with anxiety symp-
toms, which are also associatedwith reports of sexual difficul-
ties [10, 11] and often with obsessive-compulsive symptoms,
known to be associatedwith loss of sexual pleasure and sexual
dissatisfaction [12, 13]. But depression exerts adverse effects
on the full range of the sexual response, including the ability
to achieve and maintain penile erection or attain adequate
vaginal moistening and to achieve ejaculation or orgasm
[14]. Most antidepressant drugs can exert untoward effects
on sexual function and satisfaction, but when considering
the relative risks for and management of sexual dysfunction
associated with antidepressant treatment, the adverse effects
of depression itself—and of any coexisting physical illness or
concomitant medication—can be easy to overlook.
2. Relative Incidence of
Sexual Dysfunction during
Antidepressant Treatment
Accurate identification of the incidence of “treatment-
emergent” sexual dysfunction (including both the worsen-
ing of preexisting problems and the development of new
sexual difficulties in previously untroubled patients) dur-
ing antidepressant treatment has proved troublesome. Two
international studies of the prevalence of sexual dysfunction
in depressed patients prescribed either a selective sero-
tonin reuptake inhibitor or serotonin-noradrenaline reuptake
inhibitor, which take account of the presence of self-reported
sexual problems prior to starting antidepressant and of the
presence of concomitant medication sometimes implicated
in causing sexual difficulties, suggest that 27–65% of female
and 26–57% of male patients experience either a worsening
of preexisting difficulties or the emergence of new sexual
difficulties in the early stages of treatment, the differences in
prevalence partly reflecting variations in case ascertainment
and local clinical practice [15, 16].
Elucidation of the relative incidence of treatment-
emergent sexual dysfunction with differing antidepressants
has also proved difficult. Ideally, studies should be prospec-
tive, randomized, double-blind, and placebo-controlled in
a defined diagnostic group, with an assessment of sexual
function at baseline, and direct comparisons between drugs,
prescribed at doses of equivalent efficacy. In addition, sex-
ual dysfunction should be assessed with a reliable, valid
and sensitive rating scale, rather than relying on reports
or open questions which could be interpreted variably by
Table 1: Estimated proportion and relative likelihood of treatment-
emergent sexual dysfunction (derived from Serretti and Chiesa
[17]).
Antidepressant 𝑛 (sample) % sexual dysfunction Odds ratio
Moclobemide 28 0.23 .22
Agomelatine 228 3.94 .25
Amineptine 29 7.14 .46
Nefazodone 50 0.46 .46
Bupropion 645 10.38 .75
Placebo 605 14.2 1
Mirtazapine 49 2.32 2.32
Fluvoxamine 244 25.81 3.27
Escitalopram 305 37.04 3.44
Duloxetine 274 41.60 4.36
Phenelzine 24 6.43 6.43
Imipramine 54 7.24 7.24
Fluoxetine 1718 70.76 15.59
Paroxetine 1261 16.86 16.36
Citalopram 654 78.59 20.27
Venlafaxine 610 79.83 24.42
Sertraline 970 80.3 27.43
different patients. Only a small proportion of investigations
of treatment-emergent sexual dysfunction have met these
rigorous criteria, but a series of meta-analyses together
provide reasonable evidence that antidepressants differ in
their propensity for worsening sexual function.
An early meta-analysis of studies with differing method-
ologies (including open-label, double-blind, cross-sectional,
and retrospective investigations) indicates that “treatment-
emergent sexual dysfunction” is no more common with
agomelatine, amineptine, bupropion,moclobemide,mirtaza-
pine, or nefazodone than it is with placebo, in contrast to the
situation with other antidepressants [17] (Table 1): all other
antidepressants were significantlymore likely than placebo to
be associated with sexual dysfunction, as a unitary category,
and nearly all of these were significantly more likely to be
associated with dysfunction in each stage of the normal
sexual response. A meta-analysis of randomized controlled
trials of the efficacy and tolerability of acute treatment of
major depressive episodes with “second-generation” antide-
pressants indicates that bupropion is associated with a signif-
icantly lower rate of treatment-emergent sexual dysfunction
than is seen with escitalopram, fluoxetine, paroxetine, or
sertraline [18]: this is probably due to the nonserotonergic
but predominantly noradrenergic-dopaminergic mechanism
of action of bupropion [19]. A systematic review of the rela-
tive efficacy and tolerability of mirtazapine and comparator
antidepressants in the acute treatment of major depression
suggests that mirtazapine is significantly less likely than
other antidepressants to cause adverse sexual effects [20],
which is probably related to its antagonist effects at both the
alpha-2 adrenergic receptor and the 5-HT
2C receptor [21].
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Randomized controlled trials with agomelatine suggest it has
fewer adverse effects on sexual functioning than some other
antidepressants, which is more probably due to its antagonist
effects on the 5-HT
2C receptor, rather than the agonist effects
at melatonin receptors [22–24].
3. Assessing Sexual Functioning in
Depressed Patients
There aremany risk factors for developing sexual dysfunction
during antidepressant treatment (including male gender,
older age, lower academic achievement, lack of full-time
employment, physical ill-health, multiple drug treatment,
and troubled interpersonal relationships), but only some of
these are amenable to intervention. Interindividual variations
in pharmacokinetics may be important, as the “poor metab-
olizer” status for cytochrome P450 2D6 contributes to sexual
dysfunction with paroxetine [25, 26], as does genetic varia-
tion in P-glycoprotein which affects its blood-brain barrier
transfer [27]. Both patients and health professionals may find
it embarrassing to mention and discuss sexual symptoms,
consultation [28] and recognition rates in primary care are
low [29], and recent reviews demonstrate that relying on the
spontaneous reporting of adverse events can lead to a sub-
stantial underestimation of the prevalence of sexual problems
[30, 31]. Comprehensive assessment of a depressed patient
reporting sexual difficulties whilst undergoing antidepressant
treatment can be a protracted process: although use of scales
cannot fully substitute for a sensitive but comprehensive
interview, the assessment can be facilitated by employing
screening or severity questionnaires [32]. An early review
suggested that few sexual functioning scales and question-
naires had sufficiently robust psychometric properties, but
the Arizona Sexual Experiences Scale, the Changes in Sexual
Functioning Questionnaire, the Psychotropic-Related Sexual
Dysfunction Questionnaire, and the Sex Effects Scale all
have adequate properties (including validity, reliability, and
sensitivity to change) and so can be used to monitor sexual
function and satisfaction prior to and during antidepressant
treatment [32].
4. Improvement in Sexual Function during
Antidepressant Treatment
Not all the sexual effects of antidepressants are unwanted in
all patients. For example, many men troubled by persistent
premature ejaculation can derive benefits from treatment
with either clomipramine or selective serotonin reuptake
inhibitors, on either a daily or “as required” basis [33],
and a systematic review of randomized placebo-controlled
trials with trazodone indicates that when prescribed at a
higher dosage (150–200mg per day), it is efficacious in
reducing the “psychogenic” erectile dysfunction [34]. Whilst
a substantial proportion of patients experience treatment-
emergent sexual dysfunction whilst taking antidepressants
[15, 16], the reduction of depressive symptoms through
successful antidepressant treatment can also be accompanied
by reported improvements in sexual desire and satisfaction
[35, 36]. Whilst it is thought that treatment-emergent sexual
dysfunction is a cause of nonadherence to antidepressants,
the proportion of patients that stop treatment because of
sexual problems is not established [37], and neither is the
time-course of sexual dysfunction in patients who persist
with antidepressant treatment [38].
5. Management of Sexual
Dysfunction in Depression
The international studies demonstrate that the presence of
sexual dysfunction associated with antidepressant treatment
can significantly reduce self-esteem and quality of life, and
also impose burdens on interpersonal relationships over
and above those associated with depression [15, 16, 39].
Many approaches for managing patients troubled by sexual
dysfunction associated with antidepressant drugs have been
proposed, but the number of randomised placebo-controlled
trials is limited, there is an absence of randomised controlled
data evaluating the effect of psychological interventions [40],
and none of the current approaches can be considered
“ideal.”
If patients are concerned to preserve sexual functioning,
choosing an antidepressant from the list of those regarded as
having fewer adverse effects on sexual functioning (Table 1) is
reasonable, when other considerations allow; however some
of these antidepressants have other side effects, only limited
availability, or questionable efficacy. Sexual side effects of
at least some antidepressants may be dose-related, and a
reduction in daily dosage is a commonly adopted first-line
approach to management [41] (Table 2), but this approach
may contribute to a relapse of symptoms and should be
contemplated only for patients who have achieved a full
symptomatic remission andwho have successfully completed
the continuation treatment. Regular brief interruptions of
treatment (drug holidays) have previously been proposed as
potentially useful for some antidepressants [42], but only
a proportion of patients describe improvements in sexual
function (and only with some antidepressants), depressive
symptoms tend to worsen, and discontinuation symptoms
can be troublesome [43], together making this approach to
management potentially hazardous and consequently rather
uncommon [41].
Many adjuvant compounds have been advocated for
relieving sexual dysfunction associated with antidepres-
sant drug treatment, though relatively few compounds
have been subjected to rigorous evaluation. Randomised
placebo-controlled trials indicate probable efficacy for bupro-
pion [40], olanzapine [40], testosterone gel [44], and the
phosphodiesterase-5 inhibitors sildenafil (both in male and
female patients [45, 46]) and tadalafil [47]. Comparative
studies are rare, though a placebo-controlled study found no
evidence of efficacy for augmentationwithmirtazapine, olan-
zapine, or yohimbine in female patients [48]. Augmentation
of antidepressant treatment with aripiprazole is associated
with improvements in sexual interest and satisfaction in
female depressed patients, independent of the improvement
in depressive symptoms [49]. Though switching from one
antidepressant drug to another seems reasonable and is
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Table 2: Commonly adopted strategies for managing sexual dysfunction associated with antidepressant drugs. Questionnaire survey, US
psychiatrists, expertise in managing sexual dysfunction [41]. Percentages indicate the proportion of physicians using that strategy as their
preferred intervention.
Dysfunction Most frequently used treatment strategies first-, second-, and third-line interventions
Impaired libido—men and women
First. Adding a dopaminergic agent (37.9%)
Second. Switching to another antidepressant (mostly bupropion) (44.8%)
Third. Switching to another antidepressant (mostly bupropion) (31%)
Impaired arousal—women
First. Adding a dopaminergic agent (amantadine, bupropion, stimulants) (37.9%)
Second. Adding a dopaminergic agent (amantadine, bupropion, stimulants) (20.4%)
Third. Switching to another antidepressant (mostly bupropion) (34.5%)
Impaired arousal—men
First. Adding a dopaminergic agent (mostly stimulants) (31%)
Second. Switching to another antidepressant (mostly bupropion) (31%)
Third (a). Switching to another antidepressant (mostly bupropion) (37.9%)
Third (b). Adding sildenafil, tadalafil, or vardenafil (mostly sildenafil or all three) (37.9%)
(a and b used by equal number of experts as a third choice)
Impaired orgasm—women
First. Adding a dopaminergic agent (amantadine, stimulants) (34.5%)
Second. Switching to another antidepressant (mostly bupropion) (31%)
Third. Switching to another antidepressant (mostly bupropion) (27.5%)
Impaired orgasm—men
First (a). Adding a dopaminergic agent (stimulants) (31%)
First (b). Decreasing the dose of antidepressant (31%)
Second. Switching to another antidepressant (mostly bupropion) (34.5%)
Third. Switching to another antidepressant (mostly bupropion) (31%)
(a and b used by equal number of experts as a first choice)
a commonly adopted practice [41]; placebo-controlled evi-
dence of efficacy for this approach rests on a study of
switching from sertraline to nefazodone [40]: furthermore
switching away from one drug to another may lead to
discontinuation symptoms, and the replacement drug may
prove less effective in controlling depressive symptoms.
6. The Role of Phosphodiesterase-5 Inhibitors
Nitric oxide is involved in the physiology of the sexual
response, in both men and women. In men, nitric oxide in
the corpus cavernosumof the penis binds to guanylate cyclase
receptors, which results in increased levels of cyclic guanosine
monophosphate (cGMP), leading to smooth muscle relax-
ation (vasodilation) of the intimal cushions of the helicine
arteries, which in turn leads to vasodilation, increased flow
of blood into the spongy tissue of the penis, and resulting
in erection. Sildenafil, tadalafil and vardenafil are potent and
selective inhibitors of cGMP-specific phosphodiesterase type
5 (PDE5), which is responsible for degradation of cGMP in
the corpus cavernosum.Themolecular structure of sildenafil
is similar to that of cGMP and acts as a competitive binding
agent of PDE5 in the corpus cavernosum, resulting in more
cGMP and facilitation of erection [50]. In women, the role
of nitric oxide and its interplay with estrogen are less well
understood, but phosphodiesterase type 5 inhibitor enhance-
ment of nitric oxide-cGMP in nonadrenergic-noncholinergic
signaling for women seems similar to men, and the release of
nitric oxide results in vasodilatation in clitoral and vaginal
tissues [51].
As noted above, a series of randomised placebo-
controlled trials have demonstrated that PDE-5 inhibitors
are efficacious in resolving sexual dysfunction associated
with antidepressants [45–47]. In addition, studies of men
with erectile dysfunction and depressive symptoms (but not
undergoing antidepressant treatment) indicate that prescrip-
tion of PDE-5 inhibitors is often accompanied by a reduction
in depressive symptom severity, an enhancement of quality of
life, and an improvement in interpersonal relationships [52,
53]. Furthermore, investigations in animal models indicate
that nitric oxide activity is an important vulnerability factor
in the Flinders rat depressive phenotype [54], that passage of
PDE-5 inhibitors across the “blood-brain barrier” is possible
[55], that sildenafil has antidepressant-like effects after central
muscarinic receptor blockade [56], and that administration of
sildenafil can lead to a reversal of reduced social interactive
behavior [55]. Given these observations, it could be argued
that the advent of treatment with PDE-5 inhibitors is a
“game-changer” in the management of patients with sexual
dysfunction associated with antidepressants. However like
other potential treatment approaches, PDE-5 inhibitors are
not “ideal,” having side effects such as headache, dyspepsia,
and visual disturbances and needing to be used cautiously
in patients with cardiovascular disease, which is a common
comorbidity with depression.
7. Refined Approaches to Pharmacotherapy
It seems possible that a growing understanding of the
influence of genetic polymorphisms may see the adoption
of laboratory approaches to identifying patient subgroups at
increased risk of developing sexual side effects of antidepres-
sant treatment. The genome-wide association study associ-
ated with the STAR∗Dprogramme in theUnited States shows
that ten single nucleotide polymorphisms (SNPs) may medi-
ate the effects of bupropion on sexual side effects [57], and
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another genome-wide association study in Japan indicates
that 11 SNPs are associated with sexual dysfunction asso-
ciated with the antidepressants fluvoxamine, milnacipran,
and paroxetine [58]. Smaller studies suggest that sexual
dysfunction associated with selective serotonin reuptake
inhibitors may be influenced by both the GG [59] and the
AA [60] genotype of the 5-HT
2A receptor 1438 G/A polymor-
phism.
Future management options may be extended through
the development of new antidepressant treatments with a
lower risk of causing sexual problems. These could include
compounds with effects on the 5-HT
1A receptor, or with
noradrenaline reuptake inhibitor properties or even com-
plementary approaches, such as the use of S-adenosyl-l-
methionine (SAMe) [61], Maca root (Peruvian Ginseng) [62],
or saffron [63]. At present, the evidence relating to the effects
of drugs acting on the 5-HT
1A receptor is intriguing: the
partial agonist buspirone has been used to reduce sexual
dysfunction associated with selective serotonin reuptake
inhibitors [64, 65], and the partial agonist gepirone improves
sexual functioning in depressed men, independent of antide-
pressant or anxiolytic effects [66]. The novel antidepressant
drug vilazodone, which has both selective serotonin reuptake
inhibitor and 5-HT
1A partial agonist properties, appears to
have a low incidence of adverse effects on sexual functioning
[67, 68], as does the “multimodal” compound LuAA21004
(vortioxetine), whose pharmacological properties include full
agonism at the 5-HT
1A receptor [69]. However, the exper-
imental 5-HT
1A full agonist VML-670 was not efficacious
in reversing sexual dysfunction associated with fluoxetine or
paroxetine [70], and preclinical studies suggest that selective
5-HT
1A antagonists can both prevent and reverse fluoxetine-
induced sexual dysfunction in rats [71].
Although the antidepressant efficacy of the selective
noradrenaline reuptake inhibitor is limited [72], randomised
controlled trials indicate that it probably has fewer adverse
effects on sexual function than selective serotonin reup-
take inhibitors [35, 73, 74]. These findings could encourage
the further development of compounds with noradrenaline
reuptake inhibitory properties as part of their mechanism
of action: a proof-of-concept placebo-controlled study with
the novel “triple reuptake inhibitor” amitifadine suggests
that it has a low propensity to worsen sexual function in
depressed patients [75], though the novel noradrenaline
reuptake inhibitor LY22166884 was associated with signifi-
cantly more sexual adverse events than placebo in a recent
large placebo-controlled trial [7].
Whilst these findings suggest a prospect for novel antide-
pressant treatments, less likely to be associated with sexual
adverse effects than many of the current medications, patient
management currently rests on making the best use of
the available treatments. This involves careful but sensitive
enquiries to establish whether sexual difficulties are present,
on choosing antidepressants with a lower likelihood of wors-
ening sexual dysfunction, when other considerations allow;
on judiciously reducing antidepressant dosage, when this is
feasible; and on gaining greater familiarity with the potential
benefits and drawbacks of phosphodiesterase-5 inhibitors
and other adjuvant treatments.
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